Natera, Inc. announced the enrollment of the first patients in the SAGITTARIUS clinical trial, a global, randomized, phase III study. This trial is designed to evaluate the use of Signatera to guide personalized adjuvant treatment strategies for patients with colon cancer.
The SAGITTARIUS trial is sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme. This international collaboration underscores the broad interest in Signatera's potential.
The trial's objective is to further establish Signatera's role in optimizing treatment decisions for colon cancer patients. Successful outcomes from this Phase III study could significantly expand Signatera's clinical indications and market adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.